تحميل...

Quantification of cerivastatin toxicity supports organismal performance assays as an effective tool during pharmaceutical safety assessment

A major problem in pharmaceutical development is that adverse effects remain undetected during preclinical and clinical trials, but are later revealed after market release when prescribed to many patients. We have developed a fitness assay known as the organismal performance assay (OPA), which evalu...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Evol Appl
المؤلفون الرئيسيون: Gaukler, Shannon M., Ruff, James S., Galland, Tessa, Underwood, Tristan K., Kandaris, Kirstie A., Liu, Nicole M., Morrison, Linda C., Veranth, John M., Potts, Wayne K.
التنسيق: Artigo
اللغة:Inglês
منشور في: John Wiley and Sons Inc. 2016
الموضوعات:
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869410/
https://ncbi.nlm.nih.gov/pubmed/27247619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/eva.12365
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!